Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pabst

Showing results (301-310 of 332) with videos related to

Pageof 34
Sort By:
JCO Precision Oncology|February 17, 2022
Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete RemissionJurjen Versluis, Burak Kalin, Wendelien Zeijlemaker, et al.
The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.
British Journal of Haematology|May 26, 2025
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patientsSjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, et al.
Blood|January 5, 2017
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AMLBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.
Blood Advances|May 22, 2025
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First RelapseNiek G Van Der Maas, Dimitri A Breems, Clara P W Klerk, et al.
Blood Advances|October 22, 2025
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell EngagersGiulia Magno, Kai Rejeski, Giulia Rappa, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemiaSanne Lugthart, Stefan Gröschel, H Berna Beverloo, et al.
Pageof 34

Showing results (301-310 of 332) with videos related to

Sort By:
Pageof 34
JCO Precision Oncology|February 17, 2022
Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete RemissionJurjen Versluis, Burak Kalin, Wendelien Zeijlemaker, et al.
The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.
British Journal of Haematology|May 26, 2025
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patientsSjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, et al.
Blood|January 5, 2017
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AMLBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.
Blood Advances|May 22, 2025
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First RelapseNiek G Van Der Maas, Dimitri A Breems, Clara P W Klerk, et al.
Blood Advances|October 22, 2025
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell EngagersGiulia Magno, Kai Rejeski, Giulia Rappa, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemiaSanne Lugthart, Stefan Gröschel, H Berna Beverloo, et al.
Pageof 34